0925 ET - Restaurant executives say they haven't seen a big impact on their sales from GLP-1 weight-loss drugs, but they are prompting some concerns. Darden Restaurants says it's watching if the drugs curb sales at its fine-dining brands, which tend to attract higher-income consumers who could more readily afford the drugs. Fiscal 2Q same-store sales at Darden's fine-dining segment fell 5.8% as consumers who traded up to the brands last year are now more price conscious, shifting back to more affordable casual-dining, the company says. (heather.haddon@wsj.com; @heatherhaddon)
(END) Dow Jones Newswires
December 19, 2024 09:25 ET (14:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.